Mycamine(micafungin)
Mycamine (micafungin) is a small molecule pharmaceutical. Micafungin was first approved as Mycamine on 2005-03-16. It is used to treat candidemia and mycoses in the USA. It has been approved in Europe to treat candidiasis.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Mycamine (generic drugs available since 2019-05-17)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| micafungin | ANDA | 2023-06-15 |
| mycamine | New Drug Application | 2022-07-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| candidemia | EFO_1001282 | D058387 | — |
| mycoses | — | D009181 | B35-B49 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MICAFUNGIN SODIUM, MYCAMINE, ASTELLAS | |||
| 2023-06-20 | PED | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2248 | Injection, micafungin sodium, 1 mg |
Clinical
Clinical Trials
59 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Candidiasis | D002177 | B37 | — | 3 | 5 | 3 | — | 10 | |
| Invasive candidiasis | D058365 | EFO_1001283 | B37 | 3 | 1 | 2 | 3 | — | 9 |
| Candidemia | D058387 | EFO_1001282 | 2 | 1 | 2 | 2 | — | 7 | |
| Aspergillosis | D001228 | EFO_0007157 | B44 | — | 3 | 1 | 1 | — | 5 |
| Neutropenia | D009503 | D70 | 1 | 1 | — | 1 | — | 3 | |
| Liver transplantation | D016031 | EFO_0010682 | — | — | 1 | 1 | — | 2 | |
| Myeloid leukemia acute | D015470 | C92.0 | — | 1 | — | 1 | — | 2 | |
| Invasive pulmonary aspergillosis | D055744 | B44.0 | — | 1 | — | 1 | — | 2 | |
| Myelodysplastic syndromes | D009190 | D46 | — | — | — | 1 | — | 1 | |
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | 1 | — | 1 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mycoses | D009181 | B35-B49 | 3 | 3 | 4 | — | — | 10 | |
| Invasive fungal infections | D000072742 | — | 1 | 1 | — | 3 | 5 | ||
| Oral candidiasis | D002180 | EFO_0007406 | B37.0 | — | — | 2 | — | — | 2 |
| Fungemia | D016469 | B49 | — | — | 2 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | 1 | — | — | — | 1 |
| Febrile neutropenia | D064147 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MICAFUNGIN |
| INN | micafungin |
| Description | Micafungin is a cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy. It has a role as an antiinfective agent. It is an echinocandin and an antibiotic antifungal drug. |
| Classification | Small molecule |
| Drug class | antifungal antibiotics (undefined group) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCOc1ccc(-c2cc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@H](O)CC(N)=O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)c(OS(=O)(=O)O)c5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)no2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 235114-32-6 |
| RxCUI | 325887 |
| ChEMBL ID | CHEMBL457547 |
| ChEBI ID | 600520 |
| PubChem CID | 477468 |
| DrugBank | DB01141 |
| UNII ID | R10H71BSWG (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,961 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
913 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more